Foley J E, Bell P A
Diabetes Department, Sandoz Pharmaceutical Corp., E. Hanover, N.J. 07036.
Ann Med. 1990 Jun;22(3):177-9. doi: 10.3109/07853899009147265.
The rationale for pharmacologically increasing the transcription of the insulin responsive-glucose transporter of muscle and fat in diabetes is presented. The experimental approaches to achieve such a goal are outlined as well as a delineation of the assumptions and potential problems associated with this approach.